Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Dental Tribune U.S. Edition

Dental Tribune U.S. Edition | September 2013A16 iNduStry NEWS Ad Irrigation needles’ swirl effect optimizes cleansing Calasept Irrigation Needles, available from Wykle Research, are double-side-vented, luer-lock irrigation needles that optimize the cleansing of canals, creating a ‘swirl effect.’ Photo/Provided by Wykle Research Calasept Irrigation Needles, available from Wykle Research, are double side- vented, luer-lock irrigation needles that optimize cleansing of canals, creating a “swirl effect.” They are available in 27 g or 31 g, in packs of 40. Features include: • Bendability • Luer-lock hub • Sterile and disposable • Ease in cleaning roots • High-quality stainless steel Also available are Calasept Irriga- tion Syringes, which are color-coded to eliminate risk when using mul- tiple irrigation liquids. They are avail- able in packs of 20, 10 white and 10 green. These products complement Wykle’s Calasept line, which includes Calasept and Calasept Plus calcium hy- droxide paste for temporary filling of root canals. The Calasept products are manufac- tured by Nordiska Dental of Sweden. For more information, contact Wykle Research at (800) 859-6641 or visit www. wykleresearch.com. (Source: Wykle Research) C3 Jian Inc., a Los Angeles-based private biotechnology company focused on im- proving oral health care, has completed a phase-one clinical trial related to its pep- tide therapeutic product, referred to as C16G2, meant for dental caries prevention. The clinical trial was a randomized, dou- ble blind, placebo-controlled study that in- cluded a dose escalation period. The trial evaluated safety and pharmaco- kinetics, along with initial microbiology of C16G2 administered to healthy adults in a single oral dose of mouth rinse. A total of 36 subjects were in the study. No C16G2-related events, nor severe or seri- ous adverse events, were reported. The study was conducted at New York University's Bluestone Center for Clinical Research. Mark Wolff, DDS, PhD, professor and chairman of the department of cariol- ogy and comprehensive care at NYU Col- legeofDentistry,wasprincipalinvestigator. “With the current C16G2 safety informa- tion and initial microbiology, both pro- vided support to move into our phase-two development program, which we are eager to commence at the end of this year,” said Laura A. Navalta, C3 Jian vice president of clinical operations. Dentalcariesisthemostcommonchron- ic childhood disease, according to the U.S. SurgeonGeneral.IntheUnitedStates,more than $100 billion is spent annually on oral health expenditrues, the majority directly related to caries. About C3 Jian Inc. C3 Jian is a clinical-stage biotechnology company developing and commercializ- ing novel products to diagnose, treat and prevent diseases related to oral health. For more information about the company, you can visit www.c3-jian.com. (Source: C3 Jian) Testing of new dental caries prevention product progresses